Detection of in vivo enzyme activity with CatalyCEST MRI

Byunghee Yoo, Vipul R. Sheth, Christine M. Howison, Matthew J K Douglas, Carlos T. Pineda, Erin A. Maine, Amanda F Baker, Mark "Marty" Pagel

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose CatalyCEST MRI compares the detection of an enzyme-responsive chemical exchange saturation transfer (CEST) agent with the detection of an unresponsive "control" CEST agent that accounts for other conditions that influence CEST. The purpose of this study was to investigate the feasibility of in vivo catalyCEST MRI. Methods CEST agents that were responsive and unresponsive to the activity of urokinase plasminogen activator were shown to have negligible interaction with each other. A CEST-fast imaging with steady state precession (FISP) MRI protocol was used to acquire MR CEST spectroscopic images with a Capan-2 pancreatic tumor model after intravenous injection of the CEST agents. A function of (super)-Lorentzian line shapes was fit to CEST spectra of a region-of-interest that represented the tumor. Results The CEST effects from each agent showed the same initial uptake into tumor tissues, indicating that both agents had the same pharmacokinetic transport rates. Starting 5 min after injection, CEST from the enzyme-responsive agent disappeared more quickly than CEST from the unresponsive agent, indicating that the enzyme responsive agent was being catalyzed by urokinase plasminogen activator, while both agents also experienced net pharmacokinetic washout from the tumor. Conclusion CatalyCEST MRI demonstrates that dynamic tracking of enzyme-responsive and unresponsive CEST agents during the same in vivo MRI study is feasible.

Original languageEnglish (US)
Pages (from-to)1221-1230
Number of pages10
JournalMagnetic Resonance in Medicine
Volume71
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Plasminogen Activators
Urokinase-Type Plasminogen Activator
Enzymes
Neoplasms
Pharmacokinetics
Intravenous Injections
Injections

Keywords

  • CEST MRI
  • contrast agents
  • enzyme activity
  • molecular imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Yoo, B., Sheth, V. R., Howison, C. M., Douglas, M. J. K., Pineda, C. T., Maine, E. A., ... Pagel, M. M. (2014). Detection of in vivo enzyme activity with CatalyCEST MRI. Magnetic Resonance in Medicine, 71(3), 1221-1230. https://doi.org/10.1002/mrm.24763

Detection of in vivo enzyme activity with CatalyCEST MRI. / Yoo, Byunghee; Sheth, Vipul R.; Howison, Christine M.; Douglas, Matthew J K; Pineda, Carlos T.; Maine, Erin A.; Baker, Amanda F; Pagel, Mark "Marty".

In: Magnetic Resonance in Medicine, Vol. 71, No. 3, 03.2014, p. 1221-1230.

Research output: Contribution to journalArticle

Yoo, B, Sheth, VR, Howison, CM, Douglas, MJK, Pineda, CT, Maine, EA, Baker, AF & Pagel, MM 2014, 'Detection of in vivo enzyme activity with CatalyCEST MRI', Magnetic Resonance in Medicine, vol. 71, no. 3, pp. 1221-1230. https://doi.org/10.1002/mrm.24763
Yoo B, Sheth VR, Howison CM, Douglas MJK, Pineda CT, Maine EA et al. Detection of in vivo enzyme activity with CatalyCEST MRI. Magnetic Resonance in Medicine. 2014 Mar;71(3):1221-1230. https://doi.org/10.1002/mrm.24763
Yoo, Byunghee ; Sheth, Vipul R. ; Howison, Christine M. ; Douglas, Matthew J K ; Pineda, Carlos T. ; Maine, Erin A. ; Baker, Amanda F ; Pagel, Mark "Marty". / Detection of in vivo enzyme activity with CatalyCEST MRI. In: Magnetic Resonance in Medicine. 2014 ; Vol. 71, No. 3. pp. 1221-1230.
@article{863242c70fe445cca39a0e595febce7a,
title = "Detection of in vivo enzyme activity with CatalyCEST MRI",
abstract = "Purpose CatalyCEST MRI compares the detection of an enzyme-responsive chemical exchange saturation transfer (CEST) agent with the detection of an unresponsive {"}control{"} CEST agent that accounts for other conditions that influence CEST. The purpose of this study was to investigate the feasibility of in vivo catalyCEST MRI. Methods CEST agents that were responsive and unresponsive to the activity of urokinase plasminogen activator were shown to have negligible interaction with each other. A CEST-fast imaging with steady state precession (FISP) MRI protocol was used to acquire MR CEST spectroscopic images with a Capan-2 pancreatic tumor model after intravenous injection of the CEST agents. A function of (super)-Lorentzian line shapes was fit to CEST spectra of a region-of-interest that represented the tumor. Results The CEST effects from each agent showed the same initial uptake into tumor tissues, indicating that both agents had the same pharmacokinetic transport rates. Starting 5 min after injection, CEST from the enzyme-responsive agent disappeared more quickly than CEST from the unresponsive agent, indicating that the enzyme responsive agent was being catalyzed by urokinase plasminogen activator, while both agents also experienced net pharmacokinetic washout from the tumor. Conclusion CatalyCEST MRI demonstrates that dynamic tracking of enzyme-responsive and unresponsive CEST agents during the same in vivo MRI study is feasible.",
keywords = "CEST MRI, contrast agents, enzyme activity, molecular imaging",
author = "Byunghee Yoo and Sheth, {Vipul R.} and Howison, {Christine M.} and Douglas, {Matthew J K} and Pineda, {Carlos T.} and Maine, {Erin A.} and Baker, {Amanda F} and Pagel, {Mark {"}Marty{"}}",
year = "2014",
month = "3",
doi = "10.1002/mrm.24763",
language = "English (US)",
volume = "71",
pages = "1221--1230",
journal = "Magnetic Resonance in Medicine",
issn = "0740-3194",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Detection of in vivo enzyme activity with CatalyCEST MRI

AU - Yoo, Byunghee

AU - Sheth, Vipul R.

AU - Howison, Christine M.

AU - Douglas, Matthew J K

AU - Pineda, Carlos T.

AU - Maine, Erin A.

AU - Baker, Amanda F

AU - Pagel, Mark "Marty"

PY - 2014/3

Y1 - 2014/3

N2 - Purpose CatalyCEST MRI compares the detection of an enzyme-responsive chemical exchange saturation transfer (CEST) agent with the detection of an unresponsive "control" CEST agent that accounts for other conditions that influence CEST. The purpose of this study was to investigate the feasibility of in vivo catalyCEST MRI. Methods CEST agents that were responsive and unresponsive to the activity of urokinase plasminogen activator were shown to have negligible interaction with each other. A CEST-fast imaging with steady state precession (FISP) MRI protocol was used to acquire MR CEST spectroscopic images with a Capan-2 pancreatic tumor model after intravenous injection of the CEST agents. A function of (super)-Lorentzian line shapes was fit to CEST spectra of a region-of-interest that represented the tumor. Results The CEST effects from each agent showed the same initial uptake into tumor tissues, indicating that both agents had the same pharmacokinetic transport rates. Starting 5 min after injection, CEST from the enzyme-responsive agent disappeared more quickly than CEST from the unresponsive agent, indicating that the enzyme responsive agent was being catalyzed by urokinase plasminogen activator, while both agents also experienced net pharmacokinetic washout from the tumor. Conclusion CatalyCEST MRI demonstrates that dynamic tracking of enzyme-responsive and unresponsive CEST agents during the same in vivo MRI study is feasible.

AB - Purpose CatalyCEST MRI compares the detection of an enzyme-responsive chemical exchange saturation transfer (CEST) agent with the detection of an unresponsive "control" CEST agent that accounts for other conditions that influence CEST. The purpose of this study was to investigate the feasibility of in vivo catalyCEST MRI. Methods CEST agents that were responsive and unresponsive to the activity of urokinase plasminogen activator were shown to have negligible interaction with each other. A CEST-fast imaging with steady state precession (FISP) MRI protocol was used to acquire MR CEST spectroscopic images with a Capan-2 pancreatic tumor model after intravenous injection of the CEST agents. A function of (super)-Lorentzian line shapes was fit to CEST spectra of a region-of-interest that represented the tumor. Results The CEST effects from each agent showed the same initial uptake into tumor tissues, indicating that both agents had the same pharmacokinetic transport rates. Starting 5 min after injection, CEST from the enzyme-responsive agent disappeared more quickly than CEST from the unresponsive agent, indicating that the enzyme responsive agent was being catalyzed by urokinase plasminogen activator, while both agents also experienced net pharmacokinetic washout from the tumor. Conclusion CatalyCEST MRI demonstrates that dynamic tracking of enzyme-responsive and unresponsive CEST agents during the same in vivo MRI study is feasible.

KW - CEST MRI

KW - contrast agents

KW - enzyme activity

KW - molecular imaging

UR - http://www.scopus.com/inward/record.url?scp=84894421739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894421739&partnerID=8YFLogxK

U2 - 10.1002/mrm.24763

DO - 10.1002/mrm.24763

M3 - Article

C2 - 23640714

AN - SCOPUS:84894421739

VL - 71

SP - 1221

EP - 1230

JO - Magnetic Resonance in Medicine

JF - Magnetic Resonance in Medicine

SN - 0740-3194

IS - 3

ER -